News

Prana Thoracic's Series A extension round was oversubscribed by 30%, highlighting strong investor confidence and interest in the company's innovative approach to lung cancer intervention.

Imagine dusting off your Atari 2600 in today’s world of cutting-edge gaming consoles. The initial wave of nostalgia quickly gives way to the reality of clunky gameplay, 8-bit graphics, and monotonous design. It’s not 1977 anymore – we’ve grown accustomed to the high-resolution, immersive experiences that modern gaming provides.

Over the years, medical innovation has witnessed a remarkable shift from highly invasive procedures to the advent of minimally invasive technologies, improving patient care, recovery times, and overall outcomes. This journey through time showcases the ingenuity of medical professionals and the continuous pursuit of safer and more effective treatments.

Within the ever-evolving landscape of medical device development, every company must adeptly traverse distinct phases, seamlessly turning inventive concepts into devices ready for the market.

Prana Thoracic is thrilled to announce a valuable addition to our team with the appointment of Dr. Lance Black as our Chief Clinical Strategy Officer.

We are excited to introduce our outstanding interns that have joined us for summer ‍2023!

Artificial Intelligence (AI) has emerged as a game-changing technology with the potential to revolutionize healthcare across various domains, including cancer research and treatment. Lung cancer, one of the leading causes of cancer-related deaths globally, has the potential to greatly benefit from the implementation of AI-based solutions.

Immunotherapy is a promising new approach to treating cancer that is changing the strategy of cancer treatment. Immunotherapy is a type of medicine, administered intravenously, that treats cancer by using the body's own immune system to fight against the cancer. It does this by blocking the communication between the immune system and the tumor.

Prana Thoracic, a startup focused on earlier detection and intervention for lung cancer, recently won the medical devices track of the MedCity News INVEST Pitch Perfect contest. The company is developing a minimally invasive electrosurgical device to help thoracic surgeons better excise smaller and intermediate-size lung nodules.

Prana Thoracic has been selected by MedTech Innovator, the world’s largest accelerator of medical technology companies, as a part of the 2023 Accelerator Cohort.

Prana Thoracic is among ten healthcare technology startups selected for the second cohort of the University City Science Center's Capital Readiness Program.

Prana Thoracic wins the Medical Devices track in the Pitch Perfect Startup Contest hosted earlier this week at MedCity's 2023 INVEST Conference in Chicago.

Jay Salazar, Director of Product Strategy, and Dr. Richard Fischel, Chief Medical Officer and Co-Founder, attended ISMICS 2023 in Boston.

The early detection of lung cancer has long been a challenge in the field of oncology. However, with the advent of low-dose CT scans, a remarkable shift has occurred, revolutionizing the approach to lung cancer screening. Recent updates in the guidelines for screening have brought about significant changes, expanding the patient population eligible for screening and paving the way for up-and-coming screening programs. In this blog, we will explore the impact of these updated guidelines and delve into the advancements being made in lung cancer screening.

Air pollution is a major public health concern, and it has been linked to a range of health problems, including respiratory diseases, heart disease, and cancer. In particular, there is growing evidence that air pollution can promote the development of lung cancer. A new study published in Nature Communications sheds light on how air pollution can promote lung cancer by altering the activity of genes that are involved in cell growth and division.

Lung cancer is one of the leading causes of cancer deaths worldwide. It is a complex disease that can be caused by a variety of factors, such as environmental exposure, smoking, and genetic predisposition. The treatment of lung cancer can be challenging and requires a personalized approach that takes into account the unique characteristics of each patient. An important tool in this effort is comprehensive biomarker testing.

Lung cancer typically presents with symptoms later in the progression of the disease, leading to generally poor outcomes. Early stage lung cancer has been traditionally difficult to diagnose for several reasons, including lack of routine screening. This is now changing. There is now routine CT screening for lung cancer readily available and covered by many payers such as medicare. So why is adoption lagging behind? In large part it is because certain myths still prevail.

In this episode, Joanna, CEO of Prana Thoracic, shares her career journey, passion for healthcare, deep connection to Rice, and how the heartbreaking loss of her young son serves as her inspiration for finding groundbreaking medical technologies to help others.

The era of “precision” lung surgery is an exciting development that has the potential to make a significant impact on the field of lung cancer treatment in the years to come.

Prana at HLTH.

Prana Thoracic takes top prize at Ignite Healthcare Networks's annual Fire Pitch Competition.

Prana Thoracic is one of 9 startups to join the Texas Medical Center's Accelerator for HealthTech Bootcamp this fall.

Joanna Nathan joins the Houston Innovators Podcast and explains why she's taken on leading a medical device startup.

Prana Thoracic, Inc., today announced that Nucore Medical, Inc., the company’s wholly owned subsidiary has been awarded a $3M grant from the Cancer Prevention and Research Institute of Texas (“CPRIT”).